本文選題：乳腺癌 + 中藥聯(lián)合來曲唑治療��； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:通過觀察中藥聯(lián)合來曲唑治療激素依賴型乳腺癌患者病例,分析中藥聯(lián)合來曲唑治療對患者治療前后NLR、PLR水平及臨床療效的影響,探討中藥治療在激素依賴型乳腺癌臨床治療中的價值。材料與方法:選取2013年9月-2016年12月期間于遼寧中醫(yī)藥大學(xué)附屬第二醫(yī)院腫瘤科住院部符合納入標(biāo)準(zhǔn)乳腺癌病例36例,其中治療組16例,對照組20例。收集相關(guān)的臨床資料,包括年齡、中醫(yī)辨證分型、中醫(yī)證候積分、治療前后的KPS評分(卡勞夫斯基行為狀況評分)、中性粒細(xì)胞計數(shù)、血小板計數(shù)與淋巴細(xì)胞計數(shù)等。對照組口服來曲唑片2.5mg日一次行內(nèi)分泌治療;治療組在接受上述治療的同時持續(xù)口服中藥湯劑4周。應(yīng)用SPSS19.0軟件對治療前后NLR、PLR水平、KPS評分及中醫(yī)證候療效積分變化情況進(jìn)行分析。檢驗水準(zhǔn)定為P㩳0.05。結(jié)果:1.治療后治療組患者治療后NLR水平積分均值為2.10±0.78分,對照組患者治療后NLR水平積分均值為1.61±0.55分,兩組患者NLR水平差異有統(tǒng)計學(xué)意義(P0.05)。2.治療組可使患者PLR水平降低,差異有統(tǒng)計學(xué)意義(P0.05)。對照組對患者PLR水平降低無明顯影響。治療組患者治療前后PLR水平變化差異均值為26.52±43.27,對照組患者治療前后PLR水平變化差異均值為-8.18±35.81,兩組差異有統(tǒng)計學(xué)意義(P0.05)。3.治療組及對照組均可使患者KPS評分升高,差異有統(tǒng)計學(xué)意義(P0.05)。治療后組間KPS評分變化差異有統(tǒng)計學(xué)意義。治療組差值秩均值為22.41,秩和為358.5,對照組差值秩均值為15.38,秩和為307.5,兩組差值經(jīng)秩和檢驗P=0.009,差異有統(tǒng)計學(xué)意義。4.治療組及對照組均可使患者中醫(yī)證候積分降低,且觀察組效果優(yōu)于對照組,差異有統(tǒng)計學(xué)意義(P0.05)。5.PLR水平變化、患者KPS評分水平變化、中醫(yī)癥效積分水平變化與中醫(yī)證型無關(guān)。結(jié)論:1.在降低患者NLR水平方面,中藥聯(lián)合來曲唑治療及單純來曲唑治療均無明顯療效。2.中藥聯(lián)合來曲唑治療可降低患者PLR水平,并且中藥聯(lián)合來曲唑治療療效優(yōu)于單純來曲唑治療。3.中藥聯(lián)合來曲唑治療及單純來曲唑治療均可改善患者的臨床療效(提高患者KPS評分、降低中醫(yī)癥效積分),且中藥聯(lián)合來曲唑治療療效優(yōu)于單純來曲唑治療。4.PLR水平變化、患者KPS評分水平變化、中醫(yī)癥效積分水平變化與中醫(yī)證型無關(guān)。
[Abstract]:Objective: to observe the effect of traditional Chinese medicine combined with letrozole on the levels of NLRL PLR and clinical efficacy in patients with steroid-dependent breast cancer before and after treatment. To explore the value of traditional Chinese medicine in the treatment of hormone-dependent breast cancer. Materials and methods: from September 2013 to December 2016, 36 cases of breast cancer in the oncology department of the second affiliated Hospital of Liaoning University of traditional Chinese Medicine were selected, including 16 cases in the treatment group and 20 cases in the control group. To collect relevant clinical data, including age, TCM syndrome differentiation, TCM syndromes score, KPS score before and after treatment (Karoufsky behavior score, neutrophil count, platelet count and lymphocyte count, etc. The control group was treated with oral letrozole 2.5mg once a day, and the treatment group was treated with traditional Chinese medicine decoction for 4 weeks. SPSS19.0 software was used to analyze the changes of SPSS19.0 score and TCM syndromes score before and after treatment. The inspection level is set at P0. 05. The result is 1: 1. After treatment, the mean score of NLR level was 2.10 鹵0.78 in the treatment group and 1.61 鹵0.55 in the control group. There was significant difference between the two groups in NLR level. The PLR level in the treatment group was significantly lower than that in the control group (P 0.05). The control group had no significant effect on the decrease of PLR level. The difference of PLR level before and after treatment was 26.52 鹵43.27 in the treatment group and -8.18 鹵35.81 in the control group. The difference between the two groups was statistically significant (P 0.05). Both the treatment group and the control group could increase the KPS score (P 0.05). There was significant difference in KPS score between groups after treatment. The average value of difference in treatment group was 22.41, rank sum was 358.5, and that in control group was 15.38 and 307.5 respectively. The difference between the two groups was statistically significant by rank sum test (P0. 009). Both the treatment group and the control group could decrease the TCM syndrome score, and the effect of the observation group was better than that of the control group. The difference was statistically significant (P 0.05) .5.PLR level, the KPS score level of the patients, and the TCM symptom effect integral level were not related to the TCM syndrome type. Conclusion 1. In reducing the level of NLR in patients, both Chinese medicine combined with letrozole and letrozole alone have no significant curative effect. 2. 2. Chinese medicine combined with letrozole can reduce the level of PLR in patients, and the curative effect of Chinese medicine combined with letrozole is better than that of letrozole alone. 3. Traditional Chinese medicine combined with letrozole and letrozole alone can improve the clinical efficacy of the patients (improve the patients' KPS score and reduce the integral of symptomatic effect of traditional Chinese medicine, and the curative effect of traditional Chinese medicine combined with letrozole is better than that of letrozole alone. 4. The level of PLR is higher than that of letrozole alone. The change of KPS score and TCM symptom effect score were not related to TCM syndrome type.
【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王海霞;;術(shù)前中藥聯(lián)合內(nèi)分泌治療對絕經(jīng)后乳腺癌患者化療耐受性及生命質(zhì)量的影響[J];遼寧中醫(yī)雜志;2017年02期

2 鹿曉君;;雙黃益骨方對芳香化酶抑制劑致乳腺癌患者骨量丟失骨代謝的影響[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2016年32期

3 郭磊;吳棟林;杜新峰;;香貝養(yǎng)榮湯加減治療轉(zhuǎn)移性氣血兩虛乳腺癌的臨床分析[J];中國實驗方劑學(xué)雜志;2016年17期

4 張丹;詹妍;林從堯;;乳腺癌術(shù)前血常規(guī)參數(shù)與預(yù)后的關(guān)系[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年18期

5 張翼;王紅玲;韓亮;蔣士卿;;調(diào)氣消積方對乳腺癌內(nèi)分泌治療患者療效及內(nèi)分泌綜合征的影響[J];中醫(yī)學(xué)報;2016年08期

6 張劍輝;楊婧;劉穎;范春燕;張巧;文敏;陳思;;健脾益腎顆粒對乳腺癌內(nèi)分泌治療患者無病生存期及生活質(zhì)量的影響[J];中醫(yī)藥導(dǎo)報;2016年11期

7 李鵬;閆相濤;張國偉;張米娜;王慧娟;馬智勇;;血小板與淋巴細(xì)胞比值在非小細(xì)胞肺癌患者預(yù)后評估中的價值[J];中國實用醫(yī)藥;2016年13期

8 盧海松;王祥麒;姬衛(wèi)國;王俊濤;;消更散治療抗雌激素藥物所致乳腺癌患者類更年期綜合征[J];中醫(yī)學(xué)報;2016年04期

9 吳繼萍;馮妮;李藝;貝立民;李曉林;劉穎;石穎;高秉承;楊柏楓;;乳清湯干預(yù)乳腺癌氣陰虧虛證性激素水平的試驗研究[J];中醫(yī)藥信息;2016年01期

10 樸美慈;金仁順;;術(shù)前NLR PLR與乳腺癌預(yù)后的相關(guān)性[J];中國腫瘤臨床;2015年23期

相關(guān)碩士學(xué)位論文 前1條

1 朱仲麗;人外周血淋巴細(xì)胞亞群抗腫瘤效應(yīng)的研究[D];泰山醫(yī)學(xué)院;2012年

，

本文編號：1900157